Innoviva Stock Today
| INVA Stock | USD 17.39 0.02 0.11% |
PerformanceVery Weak
| Odds Of DistressVery Low
|
Innoviva is trading at 17.39 as of the 16th of March 2025, a 0.11 percent decrease since the beginning of the trading day. The stock's open price was 17.41. Innoviva has under 5 % chance of experiencing financial distress over the next 2 years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 16th of December 2024 and ending today, the 16th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 5th of October 2004 | Category Healthcare | Classification Health Care |
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California. Innoviva operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 62.68 M outstanding shares of which 8.98 M shares are currently shorted by private and institutional investors with about 19.97 trading days to cover. More on Innoviva
Moving against Innoviva Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Innoviva Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP Small-Cap 600, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Aggressive Defence, Tech Growth, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsInnoviva can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Innoviva's financial leverage. It provides some insight into what part of Innoviva's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Innoviva (INVA) is traded on NASDAQ Exchange in USA. It is located in 1350 Old Bayshore Highway, Burlingame, CA, United States, 94010 and employs 127 people. Innoviva is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.09 B. Innoviva conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 62.68 M outstanding shares of which 8.98 M shares are currently shorted by private and institutional investors with about 19.97 trading days to cover.
Innoviva currently holds about 283.58 M in cash with 188.69 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.07.
Check Innoviva Probability Of Bankruptcy
Ownership AllocationThe majority of Innoviva outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Innoviva to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Innoviva. Please pay attention to any change in the institutional holdings of Innoviva as this could imply that something significant has changed or is about to change at the company.
Check Innoviva Ownership Details
Innoviva Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-12-31 | 1.4 M | |
| Arrowstreet Capital Limited Partnership | 2024-12-31 | 1.1 M | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.1 M | |
| Bank Of America Corp | 2024-12-31 | 1.1 M | |
| Amvescap Plc. | 2024-12-31 | 1.1 M | |
| D. E. Shaw & Co Lp | 2024-12-31 | 842.6 K | |
| Deutsche Bank Ag | 2024-12-31 | 839.6 K | |
| Northern Trust Corp | 2024-12-31 | 679 K | |
| Ubs Group Ag | 2024-12-31 | 676.5 K | |
| Blackrock Inc | 2024-12-31 | 9.5 M | |
| Sarissa Capital Management Lp | 2024-12-31 | 7.3 M |
Innoviva Historical Income Statement
Innoviva Stock Against Markets
Innoviva Corporate Management
| Pavel CFA | Chief Officer | Profile | |
| Patricia Drake | I Therapeutics | Profile | |
| Marianne CPA | Chief Secretary | Profile | |
| Stephen MBA | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Innoviva. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Innoviva Stock refer to our How to Trade Innoviva Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innoviva. If investors know Innoviva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Innoviva listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.63) | Earnings Share 0.36 | Revenue Per Share | Quarterly Revenue Growth 0.07 | Return On Assets |
The market value of Innoviva is measured differently than its book value, which is the value of Innoviva that is recorded on the company's balance sheet. Investors also form their own opinion of Innoviva's value that differs from its market value or its book value, called intrinsic value, which is Innoviva's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innoviva's market value can be influenced by many factors that don't directly affect Innoviva's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innoviva's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innoviva is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Innoviva's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.